Melanie Davies of the Diabetes Research Centre at the University of Leicester in the United Kingdom
Everyone deserves care that is holistic, respectful, and tailored to their full lived experience
GLP-1 receptor agonists in nonalcoholic fatty liver disease
2024 Meta-Analysis Indicates That GLP-1RAs Reduce Adverse CV Events A 2024 Meta-analysis of 13 multiple cardiovascular outcome trials has documented that GLP1-RA therapy significantly reduces the risk of major adverse cardiovascular events (MACEs), all-cause mortality, CV mortality, stroke, risk for coronary revascularization, and composite adverse kidney outcomes in both sexes, regardless of a patient's history of cardiovascular disease, BMI or eGFR (Rivera et al, 2024)
We will continue to identify and shut down sales of these illegal and unsafe products
Aunque raras, estas complicaciones requieren atencin inmediata